Rationale and Design of the Study to Investigate the Metabolic Action of Imeglimin on Patients with Type 2 Diabetes Mellitus (SISIMAI) Authors Toshiki Kogai (ORCID: https://orcid.org/0009-0000-3126-3311) Hitoshi Naito (ORCID: https://orcid.org/0000-0001-7169-1169) Tsubasa Tajima Saori Kakehi (ORCID: https://orcid.org/0000-0002-1280-2882) Ryuzo Kawamori (ORCID: https://orcid.org/0000-0002-9686-9098) Hirotaka Watada (ORCID: https://orcid.org/0000-0001-5961-1816) Yuya Nishida (ORCID: https://orcid.org/0000-0002-8396-423X) Hideyoshi Kaga (ORCID: https://orcid.org/0000-0003-0579-2177) Naoaki Ito Yoshifumi Tamura Satoshi Kadowaki Funders Eli Lilly and Company Kowa Company Boehringer Ingelheim Japan Novo Nordisk Astellas Pharma Astellas Foundation for Research on Metabolic Disorders Eli Lilly Japan Novo Nordisk Pharma Explore the Global Research Space Interactive Map